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ABSTRACT 
Polyamidoamine drug conjugates were prepared from analogues of ferrocene and platinum. 
Standard reaction procedures were followed in the synthesis of platinum and ferrocene 
analogues. Michael addition reaction of amines to the activated double bonds of 
methylenebisacrylamide was applied for preparation of the water soluble polyamidoamine 
carriers onto which drug analogues were attached. The drug release studies of the conjugates 
were evaluated at different pH environments. The results obtained from drug release studies 
showed that rate of drug release was variable depending on the conjugate and pH 
environment. Mathematical drug release models by Korsmeyer-Peppas were used to 
determine the drug release characteristics of the ferrocene and platinum based drugs from 
polyamidoamine drug conjugates.  
Cytotoxicity potential of the analogues and polyamidoamine drug conjugates was tested on 
selected cell lines. Cisplatin was used as the standard for comparison of the IC50 values 
obtained for the compounds tested for cytotoxicity activity. The results from six polymer 
drug conjugates tested for cytotoxicity activity showed that conjugation of analogues to 
polyamidoamine carrier enhanced the activity of the analogues in some of the 
polyamidoamine drug conjugates. Various techniques such as Fourier Transform Infrared 
(FTIR) spectroscopy, Proton Nuclear Magnetic Resonance spectroscopy (1H NMR), 
Scanning Electron Microscopy (SEM), transmission electron microscopy (TEM), 
Transmission Electron Microscopy (TEM) and Energy Dispersive X-ray (EDX) spectroscopy 
were employed for the characterization of the ferrocene and platinum analogues, 
polyamidoamine carriers and drug conjugates.     
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CHAPTER 1  
___________________________________________________________________________ 
Introduction 
1.1 Background     
Polymers represent a sustainable mode of drug delivery and have been essential in the 
development and advancement of drug delivery technology by providing controlled release of 
therapeutic agents in required doses for sustained periods and tunable release of both 
hydrophobic and water soluble drugs (Liechty et al., 2010). As such polymer drug conjugates 
offer an exciting strategy for the delivery of drugs in the field of chemotherapy. 
Researches carried out over the years have proved the possibility for the synthesis of polymer 
drug conjugates from linear polymers such as polyamidoamines (Ferruti, 1996; Ferruti et al., 
2002). Cancer is among the leading causes of death worldwide, accounting for 8.8 million 
deaths in 2015. In that same period 571 000 deaths (6% of total cancer deaths) resulted from 
breast cancer (World Health Organisation, 2017). Historically, solid tumours such as breast 
cancer pose many challenges to systemic therapeutic treatment regimes. Common barriers to 
proper drug penetration in solid tumours include heterogeneous vascular supply and high 
interstitial pressures within tumour tissue. Encapsulation of drugs onto the synthetic carriers 
such as polyamidoamines can be useful in improving circulation lifetimes and hence enhance 
the drug efficacy (Park, 2002). 
Breast cancer is one of the malignant diseases in which malignant tumours emanate from 
cells of the breast. Malignant tumours are a collection of abnormal cells that have the 
capability to invade surrounding tissues or replicate into distant body parts. Breast cancer 
poses a serious threat to humanity in both the developing and the developed world. Cisplatin, 
cis-diamminedichloroplatinum(II), is the most widely used antitumor agent, finding use in 
treatment of a wide variety of cancers such as testicular, ovarian, bladder, cervical, breast, 
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head and neck and non-small cell lung cancers (Miller et al., 2010). However, several second 
generation anticancer drugs have emerged as alternatives to cisplatin and its derivatives. 
Carboplatin, one of the second generation anticancer agents, has improved therapeutic index 
of cisplatin by ameliorating some of the undesirable side effects. Lobaplatin was approved in 
China and is currently used for treatment of cisplatin resistant ovarian cancer and also breast 
cancer (Wang & Guo, 2013).  
Treatment of cancer by combination therapy is gaining in popularity because it causes 
synergistic anticancer effects, lowers individual drug related toxicity and suppresses multiple 
drug resistance (MDR) through different mechanisms of action (Parhi et al., 2012). It 
represents a mainstay treatment regime necessary for improvement of survival rates in 
cancers such as cancer of the breast (Ruiz-Esparza et al., 2014). The prevalence of MDR in 
the majority of cancers renders many clinically approved drugs ineffective, leading to poor 
prognosis (Wang & Guo, 2013). However, encapsulation of the anticancer drugs onto 
polymeric carriers can improve the water solubility of insoluble drugs, protection of the 
payload from prematurely degrading in the body, improved drug/payload residence time 
resulting in better pharmacodynamics profiles and improvement in efficacy and reduced non-
specific drug toxicity (Singh et al., 2014).  
1.2 Problem statement 
Cancer is a leading cause of death on a global scale. Several treatment modalities such as 
chemotherapy, radiation therapy and surgery have been in use for treating cancer. Platinum 
anticancer agents have been the most widely used drugs for cancer chemotherapy. However, 
the platinum drugs inflict several forms of toxicity and they are also vulnerable to drug 
resistance. For example, the use of single drug agents for breast cancer therapy is usually 
prone to drug resistance especially after sustained period of use (Persidis, 1999). Many 
convectional anticancer drugs in clinical use today have problems with resistance against one 
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or multiple strains of cancers. Some major platinum based anticancer drugs such as 
oxaliplatin and carboplatin has been found to exhibit cross resistance with cisplatin in some 
cancer types (Gore et al., 1989; Talarico et al., 1999). In addition, traditionally used 
medicinal drugs cause toxicity to healthy tissues more than therapeutic drugs incorporated to 
carriers and hence the importance of polymer drug conjugates in the delivery of drugs (Allen 
& Cullis, 2004).   
1.3 Aim and Objectives 
1.3.1 Aim 
The aim of this study was to synthesize polyamidoamine drug conjugates containing 
ferrocene and platinum analogues with enhanced therapeutic effects.  
1.3.2 Specific objectives  
 Preparation and characterization of ferrocene and platinum analogues. 
 Encapsulation of ferrocene and platinum analogues onto polyamidoamine carriers to 
form polymer drug conjugates. 
 Evaluation of drug release kinetics of encapsulated ferrocene and platinum drug 
conjugates. 
 In vitro cytotoxicity evaluation of the drug conjugates on selected cancer cell lines. 
1.4 Scope of study 
This study focuses on the preparation of polyamidoamine drug conjugates from analogues of 
ferrocene and platinum. In vitro cytotoxicity evaluation was carried out on selected cell lines 
namely MCF-7, MDA-MB-231 and EA.hy926 to assess the anticancer activity of the 
prepared polymer drug conjugates. Drug release studies of the polymer drug conjugates was 
determined at pH 1.2 and 7.4 simulating conditions experienced in the stomach and normal 
blood environment respectively. The scope of this research design is to minimize the 
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resistance of tumour cells as well as improving the efficacy of platinum based drug and 
ferrocene based drug by combining the drugs by use of water soluble polyamidoamine 
carriers. The varied working mechanisms of the two drugs that result from combination 
should overcome for drug resistance of cancerous cells. 
1.5 Significance of the study  
The research is envisaged to contribute to the chemotherapeutic treatment of breast cancer by 
ameliorating some of the problems exhibited by traditionally used drugs. Encapsulation of 
ferrocene and platinum drugs onto polymeric carriers have potential to eradicate cross 
resistance of currently used chemotherapeutic anticancer agents. Moreover, polyamidoamine 
carriers are associated with high solubility in aqueous media which is favourable for drug 
assimilation in the human body. The low cost and relative ease of preparation and 
functionalization makes PAAs ideal for use in the current study.  
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CHAPTER 2  
___________________________________________________________________________ 
     Literature Review 
2.1 Introduction 
This chapter focus on the literature based on carriers, drugs and polymer drug conjugates. 
Also included is a brief discussion on drug delivery systems such as nanoparticles, liposomes, 
hydrogels and polymeric micelles. Ferrocene and platinum analogues literature is also 
reviewed in this section. Substantial amounts of papers have been published on these topics, 
only a selected few publications have been made use of and referenced in this chapter.   
2.2 Polymeric drug carriers 
Drug carriers are materials that serve as devices to enhance the delivery and efficacy of drugs 
by increasing the hydrophilicity of drugs in water. They are employed in drug delivery 
systems such as controlled release technology to prolong in vivo actions, decrease drug 
metabolism and in the reduction of drug toxicity. Most anticancer drugs are not soluble in 
aqueous media, delaying their clinical effectiveness (Chadha et al., 2008). Hence, carriers are 
useful in improvement of drug delivery to the target sites of pharmacological actions.  
Polymers exists as natural or synthetic forms which are used widely as components in various 
branches of science. Selected polymers used as drug carriers are either natural or synthetic 
macromolecules.  In most cases synthetic polymers are more preferable for use as drug 
carriers because they can be tailor-made to match requirements of the biological conditions 
(Uchegbu & Schatzlein, 2006). In contrast, natural polymers which are present in living 
organisms suffer from low mechanical strength and high degradation rates. Polyethylene 
glycol (PEG) is one of the most used synthetic polymer for drug delivery applications 
(Greenwald et al., 2003). However, its application in therapeutics is limited by low drug 
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carrying capacity since only two terminal groups are available for drug conjugation (Banerjee 
et al., 2012; Li et al., 2013). 
                                                  
       Figure 2.1: Structure of polyethylene glycol (PEG) 
 
Polymeric drug carriers maximize their potential by ameliorating the toxicity and (or) 
increasing the therapeutic index of the anticancer drug (Larson & Ghandehari, 2012). Some 
of the major requirements of polymeric drug carriers include water solubility, 
biodegradability, biocompatibility and chemical composition as described in detail in the 
section below:   
2.2.1 Water solubility 
Solubility is a major requirement for a polymer intended to be employed as a drug carrier 
because of the predominantly aqueous central circulation system of humans. The polymer 
should be linear and highly flexible. Also, the presence of intra- or extra chain hydrophilic 
substituents such as hydroxyl and amino terminal enhances the dissolution of the whole 
structure. The hydrophilic entities are of excellent utility as they can easily undergo 
hydration. Additionally, the ability of a polymer to incorporate charged species also favours 
its hydrosolubility. The presence of the amide functional group which form the basis for 
linkage between carriers such as polyamidoamines (PAAs) and the drug also contribute to 
water solubility.  
2.2.2 Biodegradability 
Biodegradable polymers are an important collection of materials useful for the delivery of 
drugs (Liechty et al., 2010). The presence of labile bonds in polymeric backbone or linker of 
the carrier facilitates its chemical degradability. Many synthetic polymers which are 
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biodegradable depend on hydrolysis of ester linkages or derivatives of esters such as 
poly(lactic/glycolic acid) (Liechty et al., 2010). The carriers must be easily eliminated from 
the body after completion of their function or metabolized to smaller units below the renal 
threshold (Kopeèek & Ulbrich, 1983). However, the carrier should be sufficiently large to 
avoid premature excretion from the body through ultrafiltration of blood in the kidneys. 
Polymers such as poly(lactic acid) (PLA) break down to form lactic acid which is naturally 
present in muscles of the body. This acid is ejected by conversion to carbon dioxide and 
water during respiration (Gunatillake et al., 2003). Biodegradable polymers are normally 
designed to disintegrate as a result of hydrolysis of polymer chains into fragments that can be 
excreted out of the host. Failure for a drug carrier to be biodegradable may result in 
undesirable deposition and accumulation in body organs. Polyamidoamines are normally 
biodegradable especially if they contain an amide bond in the main chain and their rate of 
degradation depends on the structure (Ferruti et al., 1994; Ferruti et al., 1995).  
2.2.3 Biocompatibility 
Most importantly, a biodegradable polymer carrier is required to be biocompatible not only in 
terms of its physico-chemical properties but also with the qualities that define their 
characteristics when they come in contact with the body (Silva et al., 2004). Biocompatibility 
of a polymeric carrier is vital to ensure that rejection by the host does not happen through 
natural defence mechanisms. The polymer backbone of a carrier is required to be non-toxic, 
non-immunogenic, and non-thrombogenic in order to avoid carrier induced toxicity, 
immunogenic, and blood-clotting side effects. Methods of preparation and chemical structure 
of the polymer directly affects biocompatibility. Metabolic products resulting from the 
breakdown of the parent polymers must also be biocompatible.  
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2.2.4 Chemical composition 
The drug carrier must contain reactive functional groups suited for incorporation and release 
of drugs. To avoid steric hindrances between the drug linkers, short side chains or spacers 
should be present to separate them. In addition, spacers must be stable in blood circulation 
but susceptible to degradation by enzymes or pH-dependent hydrolysis in the lysosomal 
compartment (Kopeček, 1984; Rejmanová et al., 1985). A polymeric carrier with a high drug 
loading capacity is advantageous as it enhances the targeting efficiency for the incorporated 
drug.    
2.3 Polyamidoamine (PAA) 
Polyamidoamine carriers are a class of synthetic biodegradable polymers that can be easily 
prepared by stepwise polyaddition of aliphatic amines to bisacrylamides (Scheme 2.1). 
 
Scheme 2.1: Scheme showing synthesis of polyamidoamines (Hill et al., 1999; 
Mohammadifar et al., 2015) 
These carriers contain tertiary amino and amido groups arranged along a backbone in regular 
sequences (Ferruti, 1996;  Ferruti et al., 2002). Over the years linear PAAs have been 
principally synthesized in two forms, namely hydrogels and water-soluble entities which have 
shown potential for application as antimetastatic drugs, antivirals and antimalarials (Ferruti et 
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al., 1973; Cavalli et al., 2010; Urbán et al., 2014). The type of amide and amine present 
influence the properties of the PAAs including water solubility, degradability and biological 
toxicity. For example, the presence of primary amine and hydroxyl functional groups favours 
the solubility of polyamidoamines. 
Ferruti pioneered the polyamidoamine carriers which are nontoxic, biocompatible, water 
soluble and biodegradable (Ferruti et al., 2002). As such polyamidoamine carriers are useful 
for biomedical applications (Ferruti et al., 2002; Aderibigbe et al., 2015). PAAs also do not 
exhibit the immunogenicity disadvantage as displayed by viral delivery systems (Malgesini et 
al., 2003). They have a special property of reacting with numerous functional groups in 
organic chemistry. Several chemical functions such as hydroxyl group, carboxyl group, allyl 
group and ether group can be easily introduced to the PAAs by using corresponding 
functional monomers (Ferruti et al., 2002; Malgesini et al., 2003). An endless variety of 
polyamidoamine structures can be synthesized based on corresponding choice of monomers 
i.e. functionalized amines and bisacrylamides (Cavalli et al., 2010). Polyamidoamine 
synthesis is carried out mainly in solvents such as alcohols and water. The mechanism for the 
reaction between the bisacrylamides and amines follows Michael addition as shown in the 
scheme below: 
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Scheme 2.2: Scheme showing Michael addition mechanism in polyamidoamine formation 
 
The pioneering studies on PAA synthesis were reported around 1970 (Danusso & Ferruti, 
1970) and thereafter their chemistry and properties have been reviewed in several 
publications (Ferruti et al., 1985; Ferruti et al., 2002). Water soluble polyamidoamines have 
been extensively researched as anticancer agents by Ferruti and co-workers (Ferruti et al., 
1973; Ferruti et al., 2002; Emilitri et al., 2005). Polyamidoamine conjugates comprising 
ferrocene derivatives were synthesized in a research by Neuse et al (N’Da & Neuse, 2006). 
Aderibigbe et al. prepared PAA conjugates of neridronic acid and were characterized by 
several techniques including FTIR, NMR, TGA and SEM (Aderibigbe et al., 2015). In this 
current study, polyamidoamine conjugates of platinum drug and ferrocene derivatives will be 
prepared for drug release studies and evaluation of anticancer activity against breast cancer 
cell lines.  
2.4 Drug delivery systems 
One of the principal strategy of drug delivery is enhancement of pharmacological and 
pharmacokinetics of therapeutic drug molecules (Tong & Cheng, 2007). The drug molecules 
can be released to the target site by the dissociation of a covalent linker or by means of 
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diffusion. In designing drug delivery systems, it is important to regulate the quantity of drug 
released at a given time and the location in the body where the drug is released in order to 
optimise the efficiency of the therapeutic drug without causing harm to the host (Sing et al., 
2014). Drug delivery systems can enhance the potential of antiproliferative agents by 
increasing the concentration and (or) by reducing the exposure in normal body tissues.  
Besides the potential shown by polyamidoamines, other delivery systems have been subject 
to numerous research. Nanoparticles, liposomes, micelles and hydrogels have been used for 
drug delivery for many years with good results. 
2.4.1 Nanoparticles 
Nanoparticles offer unique approaches as drug delivery systems for treatment of cancer with 
promising viability in the biopharmaceutical industry. Nanoparticles are useful for directly 
delivery of toxic drugs to the cancerous cells. Optimization of the physicochemical and 
biological properties of nanocarriers allows for ready uptake in the tumour tissue in 
comparison to larger molecules (Suri et al., 2007). Biodegradable nanoparticles are often 
used to enhance the therapeutic value of both hydrophilic and hydrophobic drugs by 
improving water solubility, bioavailability and retention time (Shenoy & Amiji, 2005; Wang 
et al., 2012). Nanoencapsulation of medicinal drugs offer many advantages including 
protection of premature drug degradation and interaction with biological environment, 
improved absorption into target tissue and increased intracellular penetration (Alexis et al., 
2008). Studies on paclitaxel showed that nanoparticle formulation of the drug increased both 
its cytotoxicity profile in cell culture and its efficacy in in vivo analysis (Win & Feng, 2006). 
This is attributed to the increased retention time and bioavailability of nanoparticle 
formulation, which makes it possible for the concentration of the drug to remain higher than 
the minimum effective value for a longer period of time.  
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2.4.2 Liposomes 
Another extensively researched delivery platform in clinical use is the liposome drug delivery 
system which consist of lipid bilayer that can be incorporated to drugs. Liposomes vary with 
composition, surface charge, size and the method used for preparation. Ever since their 
invention by Alec Bangham in 1961 (Bangham & Horne, 1964), liposomes have been long 
considered possible delivery vehicles for drug molecules into cells that would otherwise not 
be readily internalized. The biocompatibility, biodegradability, low toxicity and 
immunogenicity of liposomes make them suitable for drug delivery. Liposomes have been 
reported to improve drugs solubility and enhance their pharmacokinetic properties such as the 
therapeutic index of anticancer agents, rapid metabolism, reduction of side effects and 
increase of in vitro and in vivo antiproliferative activity (dos Santos Giuberti et al., 2011). 
Drug release from loaded liposomes can be initiated by pH, osmotic gradient, liposome 
composition, and the nature of the surrounding environment (dos Santos Giuberti et al., 
2011). 
Doxil (PEG liposomal doxorubicin) was the first liposome based drug delivery platform to be 
approved by FDA in 1995 for treatment of AIDS related Kaposi’s Sarcoma. Other liposome 
based drug delivery systems in clinical application include DaunoXome (daunorubicin 
liposomes), DepotDur (morphine liposomes) and Ambisome (amphotericine B liposomes) 
(Farokhzad & Langer, 2006). The use of liposomes for drug delivery is firmly established 
with the clinical success of Doxil and more research is being done to find new liposome 
formulations of other anticancer drugs with better chemotherapy outcomes (Malam et al., 
2009).  
2.4.3 Polymeric micelles 
Polymeric micelles are self-assembled nanocarriers that consists of a hydrophobic core and 
shell structure. Micelles form in aqueous media when the concentration of block copolymer 
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in solution exceeds the critical micelle concentration (CMC). Hydrophobic sections of block 
copolymers start to associate at CMC in order to reduce contact with molecules of water 
resulting in the formation of a core-shell micellar structure. Typically, polymeric micelles are 
composed of several hundred block copolymers and have diameters of about 20-50 nm 
(Kwon & Okano, 1996). Similar to polymer drug conjugates, polymeric micelles improve the 
hydrophilicity and bioavailability of hydrophobic drugs due to their unique core-shell 
structure which is useful for drug encapsulation. Polymeric micelles are usually made from 
biodegradable and biocompatible materials which makes them well suited as drug carrier 
systems.  
Polymeric micelles are renowned for having high drug-loading capacity, high hydrophilicity, 
suitable size for long circulation in the blood and absorption to tumour tissues by the EPR 
effect (Rösler et al., 2001). Micelles have long half-life in the body and therefore 
advantageous for drug delivery since they are not susceptible to premature removal from 
blood stream via kidney ultrafiltration. The release of the drug from loaded polymeric micelle 
can be engineered to be triggered by physicochemical properties such as pH, temperature and 
the presence of certain types of enzymes (Rapoport, 2007).  
2.4.4 Hydrogels 
Hydrogels are three-dimensional, cross-linked networks of hydrophilic polymeric chains that 
do not dissolve but swell in water and hold a substantial amount of water while maintaining 
the structure (Qiu & Park, 2001; Hoffman, 2012). Hydrogels can be synthesized from both 
synthetic and natural polymers (Schwall & Banerjee, 2009). The pronounced 
biocompatibility of hydrogels emanate from their high water content and soft surface 
properties (Bae & Kim, 1993). The release of the drug and degradation of the polymer in the 
body is promoted by the ability of hydrogels to rapidly swell in aqueous medium (Liechty et 
al., 2010). Controlled release of the incorporated drug is also dependent on the diffusion 
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coefficient of the drug molecule across the hydrogel network (Ganta et al., 2008; Hoare & 
Kohane, 2008). Hydrogels exhibit several other properties useful for pharmaceutical and 
biomedical applications including stability in biological environment and patient compliance. 
2.5 Polymer drug conjugates 
 
Figure 2.2: Generic structure of polymer drug conjugates 
 
Polymer drug conjugates form a well-documented field of hydrophilic delivery systems 
termed polymer therapeutics (Duncan, 2006). This class of compounds also include 
polymeric drugs, polymer-protein conjugates and polymeric micelles. Polymer drug 
conjugates are mainly made up of the polymer backbone, solubilizing group, targeting 
moiety, linker and drug as shown on figure 2.2 above. Polymer drug conjugates offer several 
advantages compared to conventionally used anticancer drugs in chemotherapy. For example, 
specific targeting of drugs to the affected body organ can be used for polymer drug 
conjugates with minimal effect to healthy organs. Polymer drug conjugates, first proposed in 
1970s, are technologies for drug delivery in which a drug and polymeric carrier such as 
polyamidoamines are covalently linked (Greco & Vicent, 2009). 
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Helmut Ringsdorf introduced the concept of polymer drug conjugates in 1975 and has been in 
application since then (Ringsdorf, 1975; Gros et al., 1981). Kopecek and Duncan employed 
the same strategy to develop the first synthetic polymer-drug conjugate containing N-(2-
hydroxypropyl)methacrylamide (HPMA) (Duncan & Kopeček, 1984). Several other HPMA 
based copolymer drug conjugates such as HPMA copolymer-DACH palatinate and HPMA 
copolymer–carboplatin platinate have entered clinical trials to date [Table 2.1] (Duncan, 
2003; Duncan, 2006; Duncan & Vicent, 2010). 
Polymer drug 
conjugate 
Name  Indication Clinical trials stage 
Polyglutamate– 
paclitaxel 
CT-2103; 
XyotaxTM; 
Opaxio® 
Cancer-NSCLC, 
ovarian, various other 
cancers and 
combinations 
Phase II/III 
PEG-irinotecan NKTR-102 Cancer-metastatic 
breast 
Phase II 
Polyglutamate– 
camptothecin 
CT-2106 Various cancers Phase I 
HPMA copolymer-
DACH platinate  
Prolindac® Cancer-melanoma, 
ovarian 
Phase II 
HPMA 
copolymer– 
doxorubicin 
PK1; FCE28068  Various, particularly 
lung and breast 
cancer  
Phase II 
HPMA-
doxorubicin 
galactosamine 
PK2; FCE28069 Liver cell carcinoma Phase 1, II 
PEG-naloxone NKTR-118 Opioid-induced 
constipation 
Phase II 
Polyacetal-
camptothecin 
conjugate 
XMT-1001 
(Fleximer® 
technology) 
Various cancers Phase I 
HPMA 
copolymer– 
carboplatin 
platinate 
 
AP5280 Various cancers Phase I/II 
 
Table 2.1: Polymer drug conjugates at various stages of clinical trials (Vicent & Duncan, 
2006; Li & Wallace, 2008; Duncan, 2011) 
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Polymer drug delivery system have been useful in delivery of hydrophobic drugs e.g. 
paclitaxel (Duncan, 2006; Satchi-Fainaro et al., 2006; Haag & Kratz, 2006). An effective 
drug delivery system is characterized by high stability in blood plasma (Galanski & Keppler, 
2007), low toxicity and immunogenicity (Van Zutphen & Reedijk, 2005; Twaites et al., 
2005). Polymer drug conjugates can protect the parent drug from premature degradation, 
prevent drug from interaction with the biological environment and enhance the absorption of 
the drug into the cancerous tissue by the EPR effect (Paramjot et al., 2015). For effective 
cytotoxicity, the drug conjugate should remain in the blood for at least six hours (Wang & 
Guo, 2013). In contrast, conjugates with the ester linkage between drug and polymer can 
release incorporated drug by chemical hydrolysis or esterase degradation extracellularly 
(Sugahara et al., 2007).  
Polymer conjugation enhances the biodistribution of low-molecular-weight drugs and enables 
tumour-specific targeting with substantial reduction in toxicity. At present, over ten polymer-
anticancer drug conjugates have progressed to phase I clinical trials including polyglutamate-
camptothecin and polyacetal-camptothecin conjugate. Conjugates that have proceeded to 
phase II/III clinical trials include: polyglutamate-paclitaxel, PEG-irinotecan, HPMA 
copolymer-DACH palatinate, HPMA copolymer-doxorubicin (PK1), PEG-naloxone and 
HPMA copolymer-carboplatin palatinate (Li & Wallace, 2008). Doxorubicin is a widely used 
cytotoxic agent that has been transformed to PK1 (HPMA copolymer doxorubicin) by 
conjugation to a hydrophilic synthetic polymer, N-(2-hydroxypropyl) methacrylamide 
(HMPA) to reduce toxicity (Duncan et al., 1981; Duncan et al., 1982; Li & Wallace, 2008). 
PK1 has significantly improved plasma and tumour pharmacokinetics in comparison to the 
parent drug doxorubicin (Vasey et al., 1999).  
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Figure 2.3: Structure of PK1 (HPMA copolymer doxorubicin) 
 
Poly(l-glutamic acid)-paclitaxel (CT-2103) is a polymer drug conjugate of poly(1-glutamic 
acid) and paclitaxel. It was developed to improve the water solubility and hence the 
bioavailability of paclitaxel. The conjugate is highly hydrophilic and has showed enhanced 
antitumor activity compared to unconjugated paclitaxel in clinical studies (Li et al., 1998).  
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Figure 2.4: Structure of poly(l-glutamic acid)-paclitaxel conjugate (CT-2103) 
 
2.6 The enhanced and permeability retention (EPR) effect  
The enhanced and permeability retention effect plays a very important role in the targeting of 
polymer drug conjugates into the tumour tissue.   
 
Figure 2.5: Schematic diagram showing absorption of drug conjugate into the tumour tissue 
by the EPR effect (Wang & Guo, 2013) 
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Hydrophilic polymers, proteins and other high molecular weight long circulating 
macromolecules have the capacity to accumulate into pathological sites such as solid tumours 
and inflammations via the EPR effect which was first identified by the works of Matsumura 
and Maeda (Matsumura & Maeda, 1986). Higher molecular weight conjugates accumulate in 
tumour tissue at higher therapeutic efficacy compared to lower molecular weight conjugates 
(Shiah et al., 2001). The blood vessels in tumours, unlike normal blood vessels, are much 
leakier due to accelerated growth and hence more permeable to macromolecules (Behlau & 
Bullinger, 2009). Furthermore, the accumulation of drugs in tumour tissue is facilitated by the 
lack of an efficient lymphatic system which is responsible for the effective drainage of 
macromolecules in normal tissue. The continued accumulation of the polymer drug into the 
tumour tissue by the EPR effect is also subject to its ability to stay in blood plasma for long 
period of time. Although the EPR effect contribute significantly to the delivery of 
chemotherapeutic agents to parts of the tumour which are well-vascularized, drugs may not 
reach regions lacking adequate blood supply, thereby limiting the drug efficacy (Thakor & 
Gambhir, 2013).  
2.7 Cell cycle 
The action of chemotherapy drugs operates by interfering with ability of a cancerous cell to 
grow and thus the importance of studying the cell cycle. Drugs affect cells at certain phases 
of the cell cycle than at others.  
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              Figure 2.6: Stages of cell development (Nobelprize.org, 2001) 
 
Cells undergo four sequential phases in order to replicate. In the first phase (G1), each cell 
prepares to replicate itself by synthesis of ribonucleic acid (RNA) and protein. Synthesis of 
deoxyribonucleic acid (DNA) occurs in the second phase (S) followed by duplication of 
chromosomes (Nobelprize.org, 2001). The third phase (G2) involves the duplication of RNA 
and protein. Finally, the cell undergoes mitosis (M) resulting in two identical functional cells 
(Burri & Lee, 2009). Cancerous cells become target of chemotherapeutic drugs because of 
their ability to replicate faster compared to normal cells.                      
2.7.1 pH of normal and cancerous cells 
Normal body cells show healthy oxygen tension in aerobic state and respiration across the 
membrane of the cell. There is free exchange of oxygen and carbon dioxide across the cell 
membrane and its pH is normally around 7.34 (Altered-states.net, 2015). In contrast, a 
tumour cell is in anaerobic state. Oxygen cannot diffuse into the cell and glucose undergoes 
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fermentation to lactic acid resulting in the pH of the cell falling to 6.5 (Mellman, 1996). The 
lactic acid can attack DNA, destroying template action. RNA is changed and the control 
mechanism of the cell collapses. In acidic medium, enzymes within the cell become toxic, 
eventually leading to death of the cell as well as the host. In general, cancerous tissues are 
mildly acidic whereas healthy tissues are slightly alkaline.  
2.8 Platinum Analogues 
Platinum based anticancer drugs form a cornerstone of modern chemotherapy regimens for 
the treatment of a variety of solid tumours. The discovery of cisplatin anticancer properties 
marked the breakthrough for the successful use of platinum analogues for cancer treatment. 
Platinum-based chemotherapy agents act during any part of cell cycle and help in treating 
several types of cancers by impairing DNA synthesis, RNA transcription and function 
(Mesotheliomaweb.org, 2015). An important aspect of the chemistry of platinum drugs 
activity in vitro and in vivo is their ability to interact with the solvent environment. For 
instance, platinum drugs are activated by aquation whereby the leaving groups are replaced 
by water inside the cellular compartment (Knox et al., 1986; Martin, 1999). The toxicity 
profile of platinum based drugs is directly connected to the ease with which the leaving 
groups are aquated. As a result, platinum complexes with highly labile ligands like chloride 
or nitrate, are very toxic whereas ligands such as bis-carboxylates, which aquates at a slower 
rate, are significantly less toxic (Wheate et al., 2010). 
However, platinum drugs use for chemotherapeutic treatment of cancer is associated with 
toxic side-effects, intrinsic and acquired resistance arising from various cancerous cells lines 
(Kartalou & Essigmann, 2001; Wheate et al., 2010). As a result, several thousands of 
platinum compounds have been developed, tested in vitro and only about 35 compounds in 
the last 40 years have reached clinical trials in order to evade the disadvantages posed by 
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cisplatin chemotherapy (Boulikas et al., 2007; Kaluderović & Paschke, 2011). Other platinum 
based drugs that have gained global approval or in use in at least one country include 
carboplatin, oxaliplatin, nedaplatin, lobaplatin and heptaplatin (Boulikas et al., 2007; Wang & 
Guo, 2013). 
Platinum analogue Cancer treatment Year of approval Status 
Cisplatin Various including testicular, 
ovarian, bladder, cervical, 
breast, head and neck and 
non-small cell lung cancers 
           1978 Worldwide approval 
Carboplatin Ovarian cancer, non-small 
cell lung cancers, small cell 
lung cancers, melanoma, 
head and neck cancer, 
thymic cancer, breast cancer 
           1989 Worldwide approval 
Oxaliplatin colorectal cancer            2002 Worldwide approval 
Nedaplatin non-small cell lung cancers, 
small cell lung cancers, 
esophageal cancer, head and 
neck tumors, bladder cancer 
           1996 Approved in Japan 
Lobaplatin Breast cancer, small cell 
lung cancers, chronic 
myeloid leukemia 
           2004 Approved in China 
Heptaplatin Gastric cancer            2005 Approved in Korea 
 
Table 2.2: Summary of some platinum analogues approved for treatment of cancer (Kelland, 
2007; Wheate et al., 2010; Kang et al., 2015) 
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2.8.1 Cisplatin 
Cisplatin (figure 2.7) was first prepared by Peyrone in 1844 and the compound became 
known as Peyrone’s chloride (Reedijk & Lohman, 1985). But it was until the 1960s when 
Rosenberg fortuitously discovered the therapeutic potential of cisplatin, cis-
diamminodichloridoplatinum(II), while working on the effects of electric field on cell 
division of Escherichia coli bacteria (Rosenberg et al., 1965). Thereafter, Rosenberg and 
coworkers successfully carried out experiments with sarcoma 180 and leukemia L1210 
bearing mice (Rosenberg & VanCamp, 1970; Kociba et al., 1970). This led to cisplatin 
progressing to phase I clinical trials in 1971 and its subsequent approval in 1978 for the 
treatment of testicular and ovarian cancer (Wong & Giandomenico, 1999; Farrell, 2005; 
Fricker, 2007). To date, cisplatin is used for the treatment of a wide spectrum of cancers 
including lung, head and neck, ovarian, bladder and testicular cancers (Reedijk & Lohman, 
1985; Reedijk, 1996; Boulikas & Vougiouka, 2003).  
Pt
ClH3N
H3N Cl  
    Figure 2.7: Chemical structure of cisplatin    
       
Despite its success, clinical use of cisplatin is associated with several disadvantages that 
include severe toxicity such as nephrotoxicity, neurotoxicity, ototoxicity and emetogensis 
(Schaefer et al., 1985; Goren et al., 1986; Alberts & Noel, 1995). In addition, cisplatin 
administration is associated with poor oral bioavailability and hence it is administered 
intravenously with extensive hydration to lower the risk of renal toxicity (Wang & Lippard, 
2005). While some side effects can be contained by combining with other drugs, 
neurotoxicity remains a major dose-limiting toxic effect. Other ways to reduce cisplatin 
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toxicities have included liposomal encapsulation and use of other approved platinum drugs to 
achieve anticancer activity close to that of cisplatin but with reduced nephrotoxicity (Muggia 
et al., 2015).  
Cisplatin resistance is either inherent within or acquired by cancerous cells (Siddik, 2003). 
The major mechanisms of resistance to cisplatin chemotherapy have been identified to result 
from several factors including reduction in cisplatin uptake into cells, modulation of 
apoptotic pathways and increased DNA repair (Boulikas & Vougiouka, 2003; Siddik, 2003; 
Rabik & Dolan, 2007; Kelland, 2007). Consequently, derivatives of cisplatin have been 
developed over the years in order to reduce the toxicity of the parent compound and also to 
reduce other problems of the parent compound such as drug resistance.  
2.8.2 Carboplatin 
Carboplatin, cis-diammine-1,10-cyclobutanedicarboxylatoplatinum(II), [Pt(C6H6O4)(NH3)2], 
(figure 2.8) is a second generation anticancer agent that was introduced in the early 1980s as 
a result of intensive work towards the improvement of cisplatin which was discovered earlier.    
Major endeavours have been devoted to determine the anticancer activity of carboplatin in 
order to come up with novel platinum based drugs with better pharmacological profiles.  
Pt
H3N
H3N
O
O
O
O  
    Figure 2.8: Chemical structure of carboplatin     
      
Carboplatin and cisplatin have similar clinical activity and both drugs are prone to resistance. 
However, carboplatin is relatively better tolerated clinically, causing less side effects such as 
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nausea, neurotoxicity, ototoxicity, and nephrotoxicity than cisplatin (dos Santos Guimarães et 
al., 2013). The reduced toxicity of carboplatin compared to cisplatin can be attributed to the 
presence of less labile leaving groups on carboplatin. Carboplatin resistance can be caused by 
the reduction in platinum uptake, increased efflux, increased DNA repair, decreased 
mismatch repair, modulation of signalling pathways or presence of quiescent non-cycling 
cells (Stewart, 2007). In clinical practice, carboplatin has replaced cisplatin in a number of 
indications treatment modalities though carboplatin chemotherapy remains more expensive 
than cisplatin (Desoize & Madoulet, 2002).  
2.8.3 Oxaliplatin 
Although carboplatin has become the dominant second-generation platinum drug, oxaliplatin 
is the most commonly used third generation platinum drug. Oxaliplatin, (trans-R,R-1,2-
diaminocyclohexane) oxalate platinum(II), (Figure 2.9) is a platinum based anticancer drug 
with a 1,2-diaminocylohexane ligand (DACH) entity. It is one of the few platinum based 
drugs to achieve global approval for various cancer treatment. Oxaliplatin and other related 
1,2 diaminocyclohexane drugs were originally prepared by Kidani and co-workers (Kidani et 
al., 1978). Oxaliplatin is the more hydrophilic derivative of tetraplatin which failed clinical 
trials (Kelland, 2007).  
                                    
NH2
NH2
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Figure 2.9: Chemical structure of oxaliplatin 
 
Oxaliplatin was selected for further development because it displayed higher efficacy and 
lower toxicity compared to cisplatin in in vivo preclinical studies and most importantly, it 
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exhibit anticancer activity against some tumours resistant to cisplatin (Desoize & Madoulet, 
2002; Muggia et al., 2015). Oxaliplatin exhibits a variety of antineoplastic activity such as 
against colorectal and gastric cancers which differs from other platinum based chemotherapy 
agents (Brunton et al., 2011). A number of phase II and III trials in solid tumours 
administering oxaliplatin in combination with other anticancer drugs against several tumours 
have suggested increased activity as compared to unconjugated oxaliplatin. Furthermore, in 
comparison to cisplatin, oxaliplatin lack nephrotoxic effects, which is attributed to the 
absence of platinum accumulation in blood plasma (Pasetto et al., 2006).  
Oxaliplatin undergo different mechanism of action to that of classical cisplatin or carboplatin 
(Boulikas et al., 2007). In spite of the fact that the actual cellular and molecular aspects of 
mechanism of oxaliplatin have not been fully understood, it appears that the intrinsic 
chemical and steric features of the non-hydrolysable diaminocyclohexane platinum adducts 
on DNA contribute to the lack of cross-resistance with both cisplatin and carboplatin drugs 
(Francesco et al., 2002). The anticancer effects of oxaliplatin are enhanced when it is taken in 
combination with established anticancer drugs such as gemcitabine, cisplatin, carboplatin and 
taxanes (Ranson & Thatcher, 1999; Raymond et al., 2002). 
2.9 Ferrocenyl Drug System 
Despite the dominance of platinum-based anticancer drugs such as cisplatin and carboplatin, 
ferrocene based compounds have exhibited significant anticancer properties to be utilised for 
the chemotherapeutic treatment of cancer. Several metal compounds have been studied as 
anticancer agents preclinically in vivo and in vitro. Ferrocene was the first metallocene to be 
discovered, and its structure was deduced by Geoffrey Wilkinson in the early 1950s   
(Wilkinson et al., 1952). Ever since, the study of ferrocene and its derivatives have increased 
rapidly due to several factors including their highly promising antiproliferative activity 
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against various murine and human cancer lines, favourable electrochemical properties and 
their unusual stability in aqueous and aerobic media (van Staveren & Metzler-Nolte, 2004). 
Several scientific researchers have indicated that some ferrocene derivatives are highly active 
in vitro and in vivo, against infections from bacteria and fungus and cancer. Ferrocene-based 
compounds that have exhibited anticancer activity include ferricenium salts, ferrocene 
conjugated to biologically active molecules and ferrocenyl compounds coordinated to other 
metals (Ornelas, 2011). The salts of ferrocenium picrate and ferrocenium trichloroacetate 
were the first iron based complexes for which antitumour activity was observed in pioneering 
research by Köpf-Maier and co-workers (Köpf-Maier et al., 1984). Unsubstituted ferrocene 
on the other hand is not active as it is not soluble in water. In this current study, an attempt 
has been made to introduce substituents to ferrocene and assess anticancer activity.  
                                                          
Figure 2.10: Structure of a ferrocene based organometallic compound, ferrocifen (Pizarro et 
al., 2010) 
Jaouen et.al explored the potential of ferrocene based organometallic, ferrocifen on treatment 
of breast cancer and other cancers. They reported that it is the presence of an organometallic 
component (ferrocene) and a pharmacophore fragment (hydroxytamoxifen), that contributes 
to the cytotoxicity and anti-oestrogenicity properties of the compounds generated (Nguyen et 
al., 2007).   
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CHAPTER 3  
___________________________________________________________________________ 
Methodology 
3.1 Introduction 
This chapter describes the materials, reagents and procedures carried out in the preparation of 
analogues, carriers and drug conjugates. Characterization techniques employed in this study 
are also discussed. 
3.2 Materials and reagents 
All preparative work for experiments in this study were carried out using distilled water. 
Ferrocene (98% Merck) and potassium tetrachloride (98% Aldrich) were used for the 
reactions to form of platinum and ferrocene analogues. Solvents such as tetrahydrofuran 
(99.5% Merck) and dichloromethane (99% Merck) were dried over molecular sieves 4 Å 
(Sigma-Aldrich) for 24 hours before use for preparation of analogues. 
Methylenebisacrylamide (Sigma-Aldrich) was used for synthetic reactions for carriers and 
conjugates. Amines such as 3-dimethylamino-1-propylamine (98% Sigma-Aldrich), 1,3-
propanediamine (Sigma-Aldrich), 4-(3-aminopropyl)morphine (Aldrich), 3-
diethylaminopropylamine (Sigma-Aldrich), dopamine (98.5% Sigma-Aldrich), 2-(2-
aminoethoxy) ethanol (Acros Organics), ethylenediamine (Sigma-Aldrich) and 2,2-
(ethlenedioxy) diethylamine (Sigma-Aldrich) were used in various stages of the preparation 
of carriers and conjugates. Triethylamine (Sigma-Aldrich) was used in the reactions forming 
carriers and drug conjugates. 1,3-propanediamine (Sigma-Aldrich), 3-dimethylamino-1-
propylamine (98% Sigma-Aldrich) and 3-diethylaminopropylamine (Sigma-Aldrich) were 
employed as linkers for the drug conjugates. Dialysis of polymer carriers and drug conjugates 
was done using cellulose dialysing membranes with molecular cut-off limits of 6000 and 
12000 respectively which were purchased from Sigma-Aldrich.  
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3.3 Preparation of platinum and ferrocene analogues  
3.3.1 Synthesis of cyclohexane-1,2-diamine dichloroplatinum(II) (DACH PtCl2)  
Potassium tetrachloroplatinate (1000 mg, 2.41 mmol) was dissolved in 13 mL distilled water 
followed by dropwise addition of DACH (275 mg, 2.41 mmol) with stirring. The resultant 
mixture was stirred at RT overnight and placed at -30°C for 24 hours. The precipitate formed 
was filtered off and washed with cold water and cold methanol. The precipitated was dried in 
an oven at 40°C for 6 hours.  
3.3.2 Synthesis of 4-Ferrocenylketobutanoic acid (Fc)  
AlCl3 (1440 mg, 10.8 mmol) was added to a stirred solution of ferrocene (2000 mg, 10.75 
mmol) dissolved in dichloromethane (10 mL). Succinic anhydride (540 mg, 5.4 mmol) was 
added in small portions followed by refluxing for 2 hours. The resulting mixture was poured 
on ice water and extraction was performed using dichloromethane. The ketoacid was 
extracted from the organic layer using sodium carbonate solution (10%) and precipitated with 
concentrated hydrochloric acid. The yellow-tan precipitate formed was filtered off, washed 
with ice-water and dried in an oven at 50-60oC (Mukaya et al., 2015).  
 
Scheme 3.1: Reaction scheme for the synthesis of 4-Ferrocenylketobutanoic acid (Fc) and 3-
[4-Ferrocenylketobutamido]propylamine (Fc-PDA) 
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3.3.3 Synthesis of 3-[4-ferrocenylketobutamido]propylamine (Fc-PDA) 
To a stirred solution of Fc (1500 mg, 5.2 mmol) dissolved in tetrahydrofuran (11 mL) was 
added N-hydroxysuccinimide (600 mg, 5.2 mmol) in small portions at RT followed by 
stirring in an ice-bath for 15 min. Thereafter DCC (1080 mg, 5.2 mmol) in THF (3 mL) was 
added dropwise and stirred for a further 4 hours in the ice-water bath, then at room 
temperature for 48 hours. The solid was filtered off and washed with THF. Thereafter, the 
filtrate and washings were combined and added dropwise to stirred solution of PDA (580 mg, 
7.9 mmol) in THF (14 mL). Stirring was carried for another 24 hours in an ice-water bath and 
then 6 hours at room temperature. The solid formed was filtered off and washed with THF. 
The filtrate and washes were combined and spun to an oily viscous liquid on a rotary 
evaporator (65°C bath temperature) (Mukaya et al., 2015).  
3.4 Reaction procedures for the preparation of carriers 
 
 
Scheme 3.2: General reaction equation for the formation of polyamidoamine drug carriers 
(Mufula & Neuse, 2011) 
Carrier 1 (PC1): MBA (500 mg, 3.24 mmol) was dissolved in 20 mL of hot distilled water. 
Upon cooling, DEP (337 mg, 2.59 mmol) and TEA (1 mL) were added and stirred for 2 
hours, followed by cooling the reaction in an ice bath and dropwise addition of PDA (71.9 
mg, 0.97 mmol). The resultant solution was flushed with argon gas and stirred at RT for an 
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additional 2 days. The solution was adjusted to pH 7 by using concentrated HCl. Exhaustive 
dialysis was performed against water, using cellulose membrane with molecular weight cut-
off 6000 for 1 day. Freeze-drying of the resulting solution produced a water soluble solid. 
Carrier 2 (PC2): By the same procedure as for carrier 1 above, MBA (500 mg, 3.24 mmol) 
in 20 mL water was reacted with APM (374 mg, 2.59 mmol) and TEA (1 mL). The mixture 
was stirred for 2 hours, followed by cooling the reaction in an ice bath and dropwise addition 
of DET (100 mg, 0.97 mmol). The resultant solution was worked up as before, dialysed and 
freeze dried to produce a water soluble solid.   
Carrier 3 (PC3): Following the same procedure for synthesis of carrier 1 above, MBA (500 
mg, 3.24 mmol) in 20 mL water was reacted with AEE (272 mg, 2.59 mmol) and TEA (1 
mL). The mixture was stirred for 2 hours, followed by cooling the reaction in an ice bath and 
dropwise addition of EDDA (144 mg, 0.97 mmol). The resultant solution was worked up as 
before, dialysed and freeze dried to produce a water soluble solid.     
Carrier 4 (PC4): By the same procedure for carrier 1 above, MBA (500 mg, 3.24 mmol) in 
20 mL water was reacted with AEE (272 mg, 2.59 mmol) and TEA (1 mL). The mixture was 
stirred for 2 hours, followed by cooling the reaction in an ice bath and dropwise addition of 
EDA (58.3 mg, 0.97 mmol). The resultant solution was worked up as before, dialysed and 
freeze dried to produce a water soluble solid.
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                                                  Amount of reactant  (mg)  
 MBA DEP PDA APM APD DET DMP EDA AEE EA DPM EDDA Yield 
(mg) 
PC1 500  337 72 - - - - - - - - - 683 
PC2 500 - - 374 - 100 - - - - - - 559 
PC3 500 - - - - - - - 272 - - 144 370 
PC4 500 - - - - - - 58 272 - - - 308 
PC5 500 - - - 88 100 198 - - - - - 496 
PC6 500 - - - - 100 198 - - - 184 - 703 
PC7 500 253 - - 88 100 - - - - - - 480 
PC8 500 253 - - 88 100 - - - - - - 837 
PC9 500 - - - - 100 198 - - 59 - - 451 
PC10 500 - 48 - - - 264 - - - - - 653 
 
    Table 3.1: Summary of the yield and quantity of reactants used in the formation of polyamidoamine carriers 
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Carrier 5 (PC5): By the same procedure for carrier 1 above, MBA (500 mg, 3.24 mmol) in 
20 mL water was reacted with DMP (198 mg, 1.94 mmol) and TEA (1 mL). The mixture was 
stirred for 2 hours, followed by cooling the reaction in an ice bath and dropwise addition of 
APD (88.4 mg, 0.97 mmol). The solution obtained was stirred at RT for an additional 24 
hours and then cooled on an ice bath before DET (100 mg, 0.97 mmol) was added dropwise. 
The resultant solution was worked up as before, dialysed and freeze dried to produce a water 
soluble solid.       
Carrier 6 (PC6): By the same procedure as for carrier 1 above, MBA (500 mg, 3.24 mmol) 
in 20 mL water was reacted with DMP (198 mg, 1.94 mmol) and TEA (1 mL). The mixture 
was stirred for 2 hours, followed by cooling the reaction in an ice bath and addition of 
dopamine (184 mg, 0.97 mmol). The solution obtained was stirred at RT for an additional 24 
hours and then cooled on an ice bath before DET (100 mg, 0.97 mmol) was added dropwise. 
The resulting solution was worked up as before, dialysed and freeze dried to produce a water 
soluble solid.   
Carrier 7 (PC7): By the same procedure as for carrier 1 above, MBA (500 mg, 3.24 mmol) 
in 20 mL water was reacted with DEP (253 mg, 1.94 mmol) and TEA (1 mL). The mixture 
was stirred for 2 hours, followed by cooling the reaction in an ice bath and addition of APD 
(88.4 mg, 0.97 mmol). The solution obtained was stirred at RT for an additional 24 hours and 
then cooled on an ice bath before DET (100 mg, 0.97 mmol) was added dropwise. The 
resultant solution was worked up as before, dialysed and freeze dried to produce a water 
soluble solid.  
Carrier 8 (PC8): By the same procedure as for carrier 1 above, MBA (500 mg, 3.24 mmol) 
in 20 mL water was reacted with DEP (253 mg, 1.94 mmol) and TEA (1 mL). The mixture 
was stirred for 2 hours, followed by cooling the reaction in an ice bath and addition of 
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dopamine (184 mg, 0.97 mmol). The solution obtained was stirred at RT for an additional 24 
hours and then cooled on an ice bath before DET (100 mg, 0.97 mmol) was added dropwise. 
The resultant solution was worked up as before, dialysed and freeze dried to produce a water 
soluble solid.  
Carrier 9 (PC9): By the same procedure as for carrier 1 above, MBA (500 mg, 3.24 mmol) 
in 20 mL water was reacted with DMP (198 mg, 1.94 mmol) and TEA (1 mL). The mixture 
was stirred for 2 hours, followed by cooling the reaction in an ice bath and addition of EA (59 
mg, 0.97 mmol). The solution obtained was stirred at RT for an additional 24 hours and then 
cooled on an ice bath before dropwise addition of DET (100 mg, 0.97 mmol). The resultant 
solution was worked up as before, dialysed and freeze dried to produce a water soluble solid. 
Carrier 10 (PC10): Following the same procedure for carrier 1 above, MBA (500 mg, 3.24 
mmol) in 20 mL water was reacted with DMP (264 mg, 2.59 mmol) and TEA (1 mL). The 
mixture was stirred for 6 hours, followed by cooling the reaction in an ice bath and dropwise 
addition of PDA (48 mg, 0.65 mmol). The resultant solution was worked up as before, 
dialysed and freeze dried to produce a water soluble solid. 
The structures of polyamidoamines carriers prepared in this study are shown below: 
Carrier 1:  
X:Y = 8:2  
CONH NHCO
N
CONH NHCO
N
N NH2
X Y
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Carrier 2: 
X:Y = 8:2   
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Carrier 3: 
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Carrier 4: 
X:Y = 8:2  
CONH NHCO
N
H2N
CONH NHCO
N
O
OH
X Y
 
   
   36 
Carrier 5: 
X:Y:Z = 6:3:1 
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Carrier 6: 
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Carrier 7: 
X:Y:Z = 6:3:1 
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Carrier 8: 
X:Y:Z = 6:3:1 
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Carrier 9: 
X:Y:Z = 6:3:1 
CONH NHCO
N
N
CONH NHCO
N
HN
NH2
Z
CONH NHCO
N
HO
X Y
 
Carrier 10:  
X:Y = 8:2   
CONH NHCO
N
N
CONH NHCO
N
NH2
X Y
 
3.5 Synthesis of polyamidoamine drug conjugates   
Conjugate 1 (PD1): MBA (500 mg, 3.24 mmol) was dissolved in 10 mL of hot distilled 
water. Upon cooling, DEP (358 mg, 2.75 mmol) was added and stirred for 6 hours at RT, 
followed by dropwise addition of DET (51 mg, 0.49 mmol) in an ice bath. The resultant 
solution was flushed with argon gas and stirred at RT for an additional 3 days. DACH PtCl2 
(186 mg, 0.49 mmol) was added to the solution of the carrier protected from light and pH was 
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adjusted to 5.5. The solution was stirred for a further 3 days with light protection after 
saturation with inert gas. The resulting solution was stirred at 65C for 24 hours. The mixture 
was filtered and exhaustive dialysis was performed for 1 day followed by freeze-drying. 
Conjugate 2 (PD2): Following the same procedure for conjugate 1 above, MBA (500 mg, 
3.24 mmol) in 10 mL water was reacted with DMP (281 mg, 2.75 mmol). The mixture was 
stirred for 6 hours, followed by cooling the reaction in an ice bath and addition of PDA (36 
mg, 0.49 mmol). The resultant solution was flushed with argon gas and stirred at RT for an 
additional 3 days. DACH PtCl2 (186 mg, 0.49 mmol) was added to the solution of the carrier 
protected from light and pH was adjusted to 5.5. The resultant solution was worked up as 
before, dialysed and freeze dried to produce a water soluble solid. 
                                                Amount of reactant  (mg)  
 MBA DEP PDA DET DMP DACH 
PtCl2 
K2PtCl4 Fc-PDA Yield 
(mg) 
PD1 500 358 - 51 - 186 - - 390 
PD2 500 - 36 - 281 186 - - 285 
PD3 500 358 - 51 - - 203 - 491 
PD4 500 - 36 - 281 - 203 - 464 
PD5 500 337 - - - - - 222 145 
PD6 1000 676 48 - - - 135 222 133 
PD7 - - - - - 123 - - 112 
 
Table 3.2: Summary of yield and quantity of reactants used in the formation of 
polyamidoamine drug conjugates 
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Conjugate 3 (PD3): MBA (500 mg, 3.24 mmol) was dissolved in 10 mL of hot distilled 
water. Upon cooling, DEP (358 mg, 2.75 mmol) was added and stirred for 6 hours, followed 
by dropwise addition of DET (51 mg, 0.49 mmol) in an ice bath. The resultant solution was 
flushed with argon gas and stirred at RT for an additional 3 days. K2PtCl4 (203 mg, 0.49 
mmol) was added to the solution of the carrier and stirring was continued for a further 24 
hours with light protection after saturation with inert gas. The resulting solution was stirred at 
45C for 40 hours and pH was strictly maintained at 5-6 for the last 0.5 hours. The mixture 
was filtered and dialysis was performed for 1 day followed by freeze-drying. 
Conjugate 4 (PD4): Following the same procedure for conjugate 3 above, MBA (500 mg, 
3.24 mmol) in 10 mL water was reacted with DMP (281 mg, 2.75 mmol). The mixture was 
stirred for 6 hours, followed by cooling the reaction in an ice bath and addition of PDA (36 
mg, 0.49 mmol). The resultant solution was flushed with argon gas and stirred at RT for an 
additional 3 days. K2PtCl4 (203 mg, 0.49 mmol) was added to the solution of the carrier and 
stirring was continued for a further 24 hours with light protection after saturation with inert 
gas. The resultant solution was worked up as before, dialysed and freeze dried to produce a 
water soluble solid. 
Conjugate 5 (PD5): MBA (500 mg, 3.24 mmol) was dissolved in 10 mL of hot distilled 
water. Upon cooling, DEP (337 mg, 2.59 mmol) and TEA (1 mL) were added and stirred for 
6 hours. The resultant solution was protected from light followed by addition of Fc-PDA (222 
mg, 0.65 mmol) dissolved in 2 mL methanol. The solution was flushed with argon gas and 
stirred at RT for an additional 3 days. The resulting mixture was concentrated on roti 
evaporator (water bath temperature 60C) to remove the volatiles and then filtered. Dialysis 
was performed against water for 1 day followed by freeze drying. 
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Conjugate 6 (PD6): MBA (1000 mg, 6.49 mmol) was dissolved in 20 mL of hot distilled 
water. Upon cooling, DEP (676 mg, 5.19 mmol) and TEA (1 mL) were added and stirred for 
6 hours at RT. The resultant solution was protected from light followed by addition of Fc-
PDA (222 mg, 0.649 mmol) dissolved in 2 mL methanol. The solution was flushed with 
argon gas and stirred at room temperature for an additional 3 days.  PDA (48 mg, 0.649 
mmol) was then added to the resulting solution followed by stirring for further 24 hours. The 
solution was concentrated on roti evaporator (water bath temperature 60C) to remove the 
volatiles and then filtered. Dialysis was performed against water for 1 day followed by freeze 
drying. 
The resultant solid was divided into two portions for preparation of co-conjugates with 
platinum based drugs. 234 mg of the first portion was dissolved in 7 mL distilled water and 
protected from light with aluminium foil. K2PtCl4 (135 mg, 0.649 mmol) was added to the 
solution and stirring was continued for a further 24 hours with light protection after saturation 
with inert gas. The resulting solution was stirred at 45C for 40 hours and pH was strictly 
maintained at 5-6 for the last 0.5 hours. The mixture was filtered and dialysis was performed 
for 1 day followed by freeze-drying. 
Conjugate 7 (PD7): 231 mg of the second portion of the conjugate prepared in the procedure 
above was dissolved in 7 mL distilled water and protected from light using aluminium foil. 
DACH PtCl2 (123 mg, 0.649 mmol) was added to the solution protected from light and pH 
was adjusted to 5.5. The solution was stirred for a further 3 days with light protection after 
saturation with inert gas. The resulting solution was stirred at 65C for 24 hours. The mixture 
was filtered and dialysis was performed for 1 day followed by freeze-drying. 
The structures of polyamidoamine drug conjugates prepared in this study are shown below: 
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Conjugate 1:  
X:Y = 8.5:1.5 
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Conjugate 2:  
X:Y = 8.5:1.5 
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Conjugate 3:  
X:Y = 8.5:1.5 
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Conjugate 4:  
X:Y = 8.5:1.5 
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Conjugate 5:  
X:Y = 8:2 
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Conjugate 6:  
X:Y:Z = 8:1:1 
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Conjugate 7:  
X:Y:Z = 8:1:1 
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3.6 Characterization techniques  
This subsection describes the analytical techniques that were used for characterization of the 
ferrocene and platinum analogues, carriers and drug conjugates that were prepared. Samples 
were characterized using various techniques including the following: Fourier transform 
infrared spectroscopy (FTIR), Transmission electron microscopy (TEM), Nuclear magnetic 
resonance (NMR), Energy dispersive X-ray spectroscopy (EDX) and Particle Size Analysis. 
3.6.1 Fourier Transform Infrared Spectroscopy (FTIR) 
In this study, FTIR analysis on analogues, carriers and drug conjugates was used to determine 
the presence of functional groups. FTIR scan for each sample was carried out in wavenumber 
range 400-4000 cm-1. PerkinElmer Two FTIR spectrometer was employed to obtain FTIR 
data. 
3.6.2 Proton Nuclear Magnetic Resonance Spectroscopy (1H NMR) 
1H NMR was carried out using D2O in a Varian Unity INOVA 300 MHz Nuclear Magnetic 
Resonance Spectrometer to elucidate the chemical structure of the analogues, carriers and 
drug conjugates. The samples for drug conjugates were set to pH 10-11 using sodium 
hydroxide to get rid of protonation.     
3.6.3 Scanning Electron Microscopy (SEM) 
Scanning electron microscopy is an analytical technique useful for obtaining surface 
morphology and crystallographic information of a sample. In this study, SEM analysis was 
carried out on JEOL JSM-6390LV scanning electron microscope instrument at an 
accelerating voltage of 15 kV. All samples were coated with a thin layer of gold before SEM 
images were obtained in order to improve the quality of results.  
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3.6.4 Transmission Electron Microscopy (TEM) and Energy Dispersive X-Ray 
Spectroscopy (EDX) 
TEM was used to determine the morphology and to provide an estimate of particle thickness 
of polyamidoamine drug conjugates. The TEM images were recorded on JEM-1200EX JEOL 
instrument. Samples of conjugates were dispersed in ethanol before a drop of the solution 
was deposited onto copper grids and allowed to dry on a filter paper at RT for 15 minutes 
prior to TEM analysis. EDX was used to determine elemental composition of 
polyamidoamine drug conjugates.  
3.6.5 Particle Size Analysis 
The particle size analysis was carried out on Malvern Zetasizer Nano ZS instrument. Each 
sample of the conjugate was dissolved in 1 mL of deionized water to form a stock solution. 
0.1 mL of the stock solution was diluted to 1 mL with deionized water, vortexed and filtered 
through 0.45 µm disc syringe filter. Refractive index of 1.348 and absorption value of 0.001 
were used in the determination of the particle sizes of samples. 
3.7 Drug release studies  
Drug release was performed on conjugates PD3, PD5 and PD6. 20 mg of conjugate dissolved 
in 2 mL distilled water was placed in a dialyses membrane. The membrane was placed in 
buffer solution of pH 1.2 and 7.4 (simulating gastric pH and blood serum pH respectively) 
and dialysis was performed using a shaker (Memmert, Germany) maintained at 37C. 4 mL 
aliquots were withdrawn and replaced by equal amount of fresh buffer solution at 40 minutes 
time intervals for the first 8 hours and then at 24 hour spacing for the next 5 days. 
Concentration of drug released were quantified by ultraviolet visible spectroscopy and atomic 
absorption spectroscopy. Pt drug released was obtained by atomic absorption spectroscopy 
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while Fe drug released was quantified using ultraviolet visible spectroscopy at wavelength 
228 nm as discussed in sections 3.7.1 and 3.7.2 below. 
3.7.1 Ultraviolet Visible Spectroscopy (UV/Vis) 
Ultraviolet visible spectroscopy was performed on Perkin Elmer Lambda 365 UV/Vis 
spectrometer. The UV/Vis spectrum of Fc-PDA was evaluated for the wavelength range of 
200 nm to 700 nm as shown in figure 3.1 below. The maximum absorption wavelength was 
obtained at 228 nm and was used for the calibration of the instrument before determining the 
quantity of ferrocene drug released.  
 
Figure 3.1: UV/Vis spectrum for Fc-PDA 
 
A stock solution of 1000 mg/L was prepared and diluted accordingly to form standard 
solutions of Fc-PDA of concentrations 100, 10, 1 and 0.1 mg/L.  Figure 3.2 shows the 
calibration curve for the ferrocene based drug, Fc-PDA. After calibration, concentrations of 
samples from drug release studies were obtained at wavelength 228 nm. Each sample 
concentration was obtained in triplicates and average values were taken. 
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Figure 3.2: Calibration curve for Fc-PDA 
 
3.7.2 Atomic absorption spectroscopy (AAS) 
Thermo Scientific iCE 3500 Series AA Spectrometer was used to determine the concentration 
of platinum drug. A stock solution of 150 mg/L was prepared and diluted accordingly to form 
standard solutions of K2PtCl4 of concentrations 100, 50, 20 and 5 mg/L. Figure 3.3 shows the 
calibration curve for the platinum based drug, K2PtCl4. After calibration of the instrument, 
aliquots were withdrawn from each sample solutions obtained in drug release studies and the 
concentration was recorded. Each sample concentration was obtained in triplicates and 
average values were taken. 
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Figure 3.3: Calibration curve for K2PtCl4 
 
3.8 In vitro analysis 
3.8.1 Cell lines 
Cytotoxicity was evaluated against breast cancer cell lines (MCF-7 and MDA-MB-231) and 
normal cell line (EA.hy926). MCF-7 (HBT-22) and MDA-MB-231 (HBT-26) cell lines were 
obtained from the American Type Culture Collection (ATCC) and the EA.hy926 cell line was 
provided as a gift from the University of North Carolina’s Lineberger Comprehensive Cancer 
Centre.  
All cells were maintained in Dulbecco’s Modified Essential Medium (DMEM) supplemented 
with 10% Foetal Calf Serum (FCS) and 2 mM glutamine in 75 mL flasks. The cells were 
maintained at 37C in an incubator humidified with an atmosphere of 5% CO2. When 
confluent, cells were washed with phosphate buffered saline (PBS) and harvested by 
detachment using 0.25% trypsin/EDTA. Centrifugation was performed on the detached cells 
in complete medium at 200 g for 5 minutes. The trypan blue (0.1%) exclusion method was 
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employed to count cell which were diluted to 5 x 104 (MCF-7 and EA.hy926) and 2.5 x 104 
(MDA-MB-231) cells/mL 10% FCS medium. 
3.8.2 Cytotoxicity assay   
Cytotoxicity was evaluated by determination of cell density with sulforhodamine B assay as 
reported by Vichai and Kirtikara with minor changes (Vichai & Kirtikara, 2006). A 100 L 
of cell suspension was seeded into a sterile, clear 96-well plates and incubated overnight in an 
atmosphere of 5% CO2 at a temperature of 37C. During incubation, cells were allowed to 
attach and then exposed to 100 L of the experimental compounds (0.01 – 100 M for 
conjugates, 0.03 – 32 M for platinum drug). Medium was used as the negative control. 
Blank and colour controls without cells were included to check for background noise and 
sterility. The plates were incubated for a period of 72 hours in 5% CO2 at a temperature of 
37C and then cells were fixed with 50 L of 50% trichloroacetic acid overnight at 4C. 
Fixed cells were washed three times with tap water before staining with 100 L of 0.057% 
SRB in 1% acetic acid for 30 minutes. The stained cells were washed four times with 100 L 
of 1% acetic acid and then air dried. The bound dye was dissolved using 200 L Tris-buffer 
(10mM, pH 10.5). Absorbance was measured on Synergy 2 plate (Bio-tek Instruments, Inc) 
at 510 nm with reference 630 nm. Assays were carried out using both three intra- and three 
inter-replicates. Graphpad Prism 5 was used to calculate the IC50 values.  
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CHAPTER 4  
___________________________________________________________________________ 
Results and Discussion 
4.1 Introduction 
This chapter describes the results of the characterization of analogues, carriers and drug 
conjugates that were prepared in this project. Drug release studies and in vitro cytotoxicity 
evaluation results are also discussed in this chapter. 
4.2 FTIR analysis 
Fig 4.1 shows the FTIR spectrum of platinum analogue cyclohexane-1,2-diamine 
dichloroplatinum(II) (DACH PtCl2) which was employed in the preparation of 
polyamidoamine drug conjugates. 
Figure 4.1: FTIR spectrum of DACH PtCl2 
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In the spectrum for DACH PtCl2, two sharp peaks at 3269 cm
-1 and 3193 cm-1 are attributed 
to the primary amine N-H stretch. Also observed are peaks corresponding to the C-N stretch 
on 1158 cm-1, C-H stretch on 2933 cm-1 and 2865 cm-1. An extremely weak band for Pt-N 
stretch appear at about 545 cm-1. Wysokiński and co-workers reported similar findings on 
carboplatin (Wysokiński et al., 2006). The FTIR analysis confirms the successful synthesis of 
the platinum analogue since all major peaks are clearly observable on the spectrum. 
Figure 4.2: FTIR spectrum of 4-ferrocenylketobutanoic acid 
The spectrum for 4-ferrocenylketobutanoic acid shows labelled sharp peak at 1715 cm-1 
ascribed to C=O stretch of a carboxylic acid. The broad peak centred on 2971 cm-1 also 
confirms the presence of O-H stretch carboxylic acid functional group. On the other hand, 
peaks on 1080 cm-1, 1656 cm-1 and 1229 cm-1 correspond to C-O stretch, C=C stretch and C-
N stretch respectively. 
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Figure 4.3: FTIR spectra of polyamidoamine carriers PC1-5 
FTIR spectra of polyamidoamine carriers (PC1-10) are shown in figs 4.3 and 4.4. Spectra for 
the carriers showed a similar trend for the major absorption peaks across all compounds. The 
presence of the broad peak centred around 3300 cm-1 (amide N-H stretch) and sharp peak in 
the range 1655-1635 cm-1 (C=O stretch) in all spectrums for polyamidoamine carriers PC1 to 
PC10 represent the amide bond and confirm the successful preparation of the carriers. Peaks 
on the range 3100-3000 cm-1 and 3000-2850 cm-1 are attributed to C-H stretching for alkene 
and alkane functional groups respectively. Sharp peaks corresponding to N-H bending were 
also observed for carriers at about 1530 cm-1 of each spectrum. For carriers PC6 and PC8, 
peaks corresponding to aromatic C-H stretch were observed at about 3053 cm-1 confirming 
the presence of dopamine in the polyamidoamine carriers. The peak at about 1217 cm-1 in 
each spectrum is attributed to C-N stretch. 
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Figure 4.4: FTIR spectra of polyamidoamine carriers PC6-10 
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Figure 4.5: FTIR spectra of polyamidoamine drug conjugates PD1-4 
The FTIR spectra of polyamidoamine drug conjugates (PD1-7) are shown in figs 4.5 and 4.6. 
The spectra of the conjugates did not differ from that of carriers to a larger extent. The broad 
peak centred around 3300 cm-1 (amide N-H stretch) and sharp peak in the range 1655-1635 
cm-1 (C=O stretch) in all spectrums for polyamidoamine conjugates PD1 to PD7 represent the 
amide bond and confirm the successful preparation of the conjugates. The presence of the 
amide bond also confirm the successful incorporation of the ferrocenyl analogue, 4-
ferrocenylketobutanoic acid (Fc) on conjugates PD5, PD6 and PD7. The peak on 545 cm-1 
corresponds to Pt-N and confirm the conjugation of the platinum analogues on the conjugates 
(Wysokiński et al., 2006).  Peaks on the range 3100-3000 cm-1 and 3000-2850 cm-1 are 
attributed to C-H stretching for alkene and alkane functional groups respectively. Sharp peaks 
corresponding to N-H bending were also observed for the conjugates at about 1530 cm-1 of 
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each spectrum. The peak at about 1217 cm-1 in each spectrum of the conjugates correspond to 
C-N stretch. 
Figure 4.6: FTIR spectra of polyamidoamine drug conjugates PD5-7 
 
4.3 1H NMR analysis 
Results obtained for 1H NMR analysis confirmed the observations obtained from FTIR 
analysis. The proton count expected and the proton count obtained were close to each other 
indicating the successful isolation of the compounds. 1H NMR spectra of the analogues and 
polymers prepared in this study were analysed and tabulated as shown in table 4.1 and 4.2 
below.  
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Compound 
 
Assignment 
 
Chemical shift 
(ppm) 
        Proton count 
Expected Found 
Fc-PDA CH2CH2CH2NH2 
CH2CH2CH2NH2 
COCH2CH2CO 
CONHCH2CH2CH2 
CH (ferrocenyl) 
2.75-2.73 
3.08-3.05 
4.22 
4.50 
4.80 
2 
2 
4 
2 
9 
2 
2 
5 
2 
2 
PC1 CH2N(CH2CH3)2 
CH2CH2CH2N(CH2CH3)2, CH2CH2CH2NH2 
CH2CH2CONH, NHCOCH2CH2 
CH2CH2CH2N(CH2CH3)2, CH2CH2CONH, COCH2CH2N, CH2CH2CH2NH2 
CONHCH2NHCO 
1.01-0.97 
1.57 
2.30-2.25 
2.73-2.34 
4.41-4.40 
48 
20 
40 
112 
20 
48 
16 
49 
117 
22 
PC2 CH2CH2CH2N(CH2)2 
CH2CH2CONH, COCH2CH2N, CH2CH2CH2N(CH2)2, CH2CH2NHCH2CH2NH2 
CH2CH2CONH, COCH2CH2N 
CH2OCH2 
CONHCH2NHCO 
1.50 
2.41-2.18  
2.66-2.61 
3.59 
4.39 
16 
120 
40 
32 
20 
16 
128 
46 
31 
22.5 
PC3 CH2CH2CONH, COCH2CH2N, NCH2CH2O, OCH2CH2NH2 
CH2CH2CONH, COCH2CH2N 
CH2OCH2CH2OH, CH2OCH2CH2OCH2 
CONHCH2NHCO 
2.31-2.26 
2.57-2.53 
3.51-3.45 
4.41-4.40 
64 
28 
64 
20 
64 
28 
60 
31 
PC4 CH2CH2CONH, COCH2CH2N  
CH2CH2CONH, COCH2CH2N, NCH2CH2O, CH2CH2NH2 
CH2OCH2CH2OH 
CONHCH2NHCO 
2.28-2.25 
2.70-2.51 
3.57-3.44 
4.40-4.39 
40 
64 
48 
20 
40 
59 
39 
19 
PC5 CH2CH2CH2N(CH3)2 
CH2CH2CONH, COCH2CH2N, CH2CH2CH2N(CH3)2, CH2CH(OH), CH2CH2NHCH2CH2NH2 
CH2CH2CONH, COCH2CH2N 
CH(OH)CH2OH 
CONHCH2NHCO 
1.65 
2.37-2.25 
2.54-2.46 
2.75-2.54 
4.44-4.41 
12 
114 
40 
9 
20 
12 
59.5 
49 
76.5 
23 
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PC6 CH2CH2CH2N(CH3)2 
CH2CH2CONH, COCH2CH2N 
CH2CH2CONH, COCH2CH2N, CH2CH2CH2N(CH3)2, CH2CH2C(CH)2, CH2CH2NHCH2CH2NH2 
CH2CH2C(CH)2 
CONHCH2NHCO 
CH (aromatic) 
1.47 
2.03 
2.41-2.13 
2.53 
4.40 
5.66-5.63 
6.09-6.08 
12 
40 
114 
6 
20 
1 
2 
12 
50 
96 
12 
17 
1 
2 
PC7 CH2N(CH2CH3)2 
CH2CH2CH2N(CH2CH3)2 
CH2CH2CONH, COCH2CH2N, CH2CH2CH2N(CH2CH3)2, CH2CH(OH), CH2CH2NHCH2CH2NH2 
CH2CH2CONH, COCH2CH2N 
CH(OH)CH2OH 
CONHCH2NHCO 
0.86-0.84 
1.47-1.43 
2.44-2.24 
2.70-2.52 
3.45-3.31 
4.40 
36 
12 
102 
40 
9 
20 
36 
11 
100 
41 
5 
20 
PC8 CH2N(CH2CH3)2 
CH2CH2CH2N(CH2CH3)2 
CH2CH2CONH, COCH2CH2N, CH2CH2CH2N(CH2CH3)2, CH2CH2C(CH)2, CH2CH2NHCH2CH2NH2 
CH2CH2CONH, COCH2CH2N 
CH2CH2C(CH)2 
CONHCH2NHCO 
CH (aromatic) 
 
0.85-0.82 
1.44 
2.41-2.01 
2.61-2.60 
3.13-3.09 
4.39 
6.08-6.06 
7.92-7.74 
36 
12 
102 
40 
6 
20 
1 
2 
36 
10 
103 
46 
4 
18 
0.2 
0.5 
PC9 CH2CH2CH2N(CH3)2 
CH2CH2CONH, COCH2CH2N, CH2CH2CH2N(CH3)2, NCH2CH2OH, CH2CH2NHCH2CH2NH2 
CH2CH2CONH, COCH2CH2N 
NCH2CH2OH 
CONHCH2NHCO 
1.50-1.44 
2.55-2.02 
2.69-2.61 
3.52-3.48 
4.40 
12 
114 
40 
6 
20 
12 
115 
43 
5 
20 
PC10 CH2CH2CH2N(CH3)2, CH2CH2CH2NH2 
CH2CH2CONH, COCH2CH2N, CH2CH2CH2N(CH3)2, CH2CH2CH2NH2 
CH2CH2CONH, NHCOCH2CH2  
CONHCH2NHCO 
1.60 
2.52-2.15 
2.72 
4.54-4.52 
20 
128 
40 
20 
20 
140 
47 
23 
   
   59 
Table 4.1: 1H NMR data for polyamidoamine drug carriers 
 
Compound 
 
Assignment 
 
Chemical shift  
(ppm) 
        Proton count 
Expected Found 
PD1 CH2N(CH2CH3)2 
CH2CH2CH2N(CH2CH3)2, CHCH2CH2CH2CH2CH  
CH2CH2CONH, NHCOCH2CH2 
CH2CH2CONH, COCH2CH2N, CH2CH2CH2N(CH2CH3)2, CH2CH2NHCH2CH2, CHCH2CH2CH2CH2CH 
CONHCH2NHCO 
0.99-0.98 
1.57 
2.30-2.26 
2.69-2.33 
4.41 
51 
29 
40 
123 
20 
51 
16 
42 
128 
21 
PD2 CH2CH2CH2N(CH3)2, CH2CH2CH2NH, CHCH2CH2CH2CH2CH 
CH2CH2CONH, COCH2CH2N, CH2CH2CH2N(CH3)2, CH2CH2CH2NH, CHCH2CH2CH2CH2CH  
CH2CH2CONH, NHCOCH2CH2 
CONHCH2NHCO 
1.61 
2.38-2.32 
2.58-2.54 
4.41 
32 
134 
40 
20 
32 
133 
40 
40 
PD3 CH2N(CH2CH3)2 
CH2CH2CH2N(CH2CH3)2 
CH2CH2CONH, COCH2CH2N, CH2CH2CH2N(CH2CH3)2, CH2CH2NHCH2CH2 
CH2CH2CONH, NHCOCH2CH2 
CONHCH2NHCO 
0.86-0.83 
1.45 
2.38-2.24 
2.64-2.61 
4.40 
51 
17 
120 
40 
20 
51 
16 
105 
34 
16 
PD4 CH2CH2CH2N(CH3)2, CH2CH2CH2NH 
CH2CH2CONH, COCH2CH2N, CH2CH2CH2N(CH3)2, CH2CH2CH2NH  
CH2CH2CONH, NHCOCH2CH2 
CONHCH2NHCO 
1.47 
2.31-2.03 
2.67-2.62 
4.40 
20 
131 
40 
20 
20 
146 
46 
20 
PD5 CH2N(CH2CH3)2 
CH2CH2CH2N(CH2CH3)2, CH2CH2CH2NH  
CH2CH2CONH, COCH2CH2N, CH2CH2CH2N(CH2CH3)2, CH2CH2CH2NH 
CH2CH2CONH, NHCOCH2CH2, COCH2CH2CO 
CONHCH2NHCO, CH (ferrocenyl) 
0.99 
1.59 
2.50-2.40 
2.76 
4.54 
48 
20 
112 
48 
38 
48 
19 
99 
45 
28 
PD6 CH2N(CH2CH3)2 
CH2CH2CH2N(CH2CH3)2, CH2CH2CH2NH  
0.98-0.96 
1.57 
48 
20 
48 
13 
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CH2CH2CONH, COCH2CH2N, CH2CH2CH2N(CH2CH3)2, CH2CH2CH2NH 
CH2CH2CONH, NHCOCH2CH2, COCH2CH2CO 
CONHCH2NHCO, CH (ferrocenyl) 
2.49-2.38 
2.74 
4.51 
112 
44 
29 
101 
41 
8 
PD7 CH2N(CH2CH3)2 
CH2CH2CH2N(CH2CH3)2, CH2CH2CH2NH, CHCH2CH2CH2CH2CH  
CH2CH2CONH, NHCOCH2CH2, COCH2CH2CO 
CH2CH2CONH, COCH2CH2N, CH2CH2CH2N(CH2CH3)2, CH2CH2CH2NH, CHCH2CH2CH2CH2CH 
CONHCH2NHCO, CH (ferrocenyl) 
1.18 
1.77 
2.44-2.39 
2.98-2.51 
4.54 
48 
28 
44 
114 
29 
48 
16 
42 
113.5 
20 
 
Table 4.2: 1H NMR data for polyamidoamine drug conjugates 
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All spectrum of carriers and conjugates showed the signal of CONHCH2NHCO at about 4.40 
ppm indicating the successful formation of the polyamidoamine backbone which form the 
basis of both polyamidoamine carriers and conjugates. The expected proton count and found 
proton count for the polymers were similar which indicate that the polyamidoamines carriers 
and conjugates were successfully isolated. 1H NMR spectrum for PC1 displayed signals of 
the methyl and methylene protons of 3-diethylaminopropylamine at 1.01-0.97 ppm, 1.57 ppm 
and 2.73-2.34 ppm. Peaks at 1.57 ppm and 2.73-2.43 ppm confirmed the incorporation of 1,3-
propanediamine to the carrier PC1. The spectra for PC2 showed signals at 1.50 ppm, 2.41-
2.31 ppm and 3.59 ppm with indicate the presence of 4-(3-aminopropyl) morphine and 
diethylene triamine in the carrier. The spectrum for PC3 showed signal 2.31-2.26 ppm and 
3.51-3.45 ppm suggesting the presence of the amines; 2-(2-aminoethoxy)ethanol and 2,2-
(ethlenedioxy) diethylamine. Spectrum for PC4 displayed peaks for methylene protons of 2-
(2-aminoethoxy) ethanol at 2.70-2.51 ppm and 3.57-3.44 ppm. Signals at 2.70-2.51 ppm 
indicate methylene protons of ethylenediamine in carrier PC4. The spectrum for PC5 showed 
peaks at 1.65 ppm, 2.37-2.25 ppm and 2.75-2.54 ppm which indicate the incorporation of 
amines; 3-dimethylamino-1-propylamine, 3-amino-1,2-propanediol and diethylene triamine. 
Spectrum for PC6 showed peaks at 2.41-2.13 ppm and 2.53 ppm which indicate the presence 
of 3-dimethylamino-1-propylamine and diethylene triamine. Peaks at 1.47 ppm, 2.41-2.13 
ppm, 5.66-5.63 ppm and 6.09-6.08 ppm confirm the incorporation of dopamine to the carrier. 
The spectrum for PC7 showed the peaks of the methyl and methylene protons of 3-
diethylaminopropylamine at 0.86-0.84 ppm, 1.47-1.43 ppm and 2.44-2.24 ppm. Signals at 
2.44-2.24 ppm and 3.45-3.31 ppm indicate the methylene protons of the amines;     3-amino-
1,2-propanediol and diethylene triamine. On the other hand, peaks at 0.86-0.84 ppm, 1.47-
1.43 ppm and 2.44-2.24 ppm indicate the presence of 3-diethylaminopropylamine in the 
carrier. The spectrum for PC8 displayed signals for the methyl and methylene protons of 3-
   
   62 
diethylaminopropylamine at 0.85-0.82 ppm, 1.44 ppm and 2.41-2.01 ppm. Signals at 2.41-
2.01 ppm, 3.13-3.09 ppm, 6.08-6.06 ppm and 7.92-7.74 ppm indicate the presence of 
diethylene triamine and dopamine in the carrier. Spectrum for PC9 showed signals at 1.50-
1.44 ppm and 2.55-2.02 ppm which confirmed the incorporation of 3-dimethylamino-1-
propylamine. On the other hand, signals at 2.55-1.44 ppm and 3.52-3.48 ppm indicate the 
presence of diethylene triamine and ethanolamine.  The spectrum for PC10 showed signals at 
1.60 ppm and 2.52-2.15 ppm which confirm the successful incorporation of 3-
dimethylamino-1-propylamine and 1,3-propanediamine to the carrier. 
The spectrum for polyamidoamine drug conjugate PD1 showed signals at 0.99-0.98 ppm, 
1.57 ppm and 2.69-2.33 ppm indicated the presence of 3-diethylaminopropylamine. Peaks at 
1.57 ppm and 2.69-2.33 ppm confirm the presence of diethylene triamine and cyclohexane-
1,2-diamine dichloroplatinum(II) in the conjugate. Spectrum for PD2 showed signals at 1.61 
ppm and 2.58-2.32 ppm indicated the presence of 3-dimethylamino-1-propylamine, 1,3-
propanediamine and cyclohexane-1,2-diamine dichloroplatinum(II). The spectrum for PD3 
displayed signals at 0.86-0.83 ppm, 1.45 ppm and 2.38-2.24 ppm which confirm the presence 
of 3-diethylaminopropylamine. Signals at 2.38-2.24 ppm indicate presence of diethylene 
triamine and potassium tetrachloroplatinate in the conjugate. Spectrum for PD4 showed peaks 
at 1.47 ppm and 2.31-2.03 ppm which confirm the presence of 3-dimethylamino-1-
propylamine, 1,3-propanediamine and potassium tetrachloroplatinate in the conjugate. The 
spectrum for PD5 displayed peaks at 0.99 ppm, 1.59 ppm and 2.50-2.40 ppm which indicate 
presence of 3-diethylaminopropylamine. Signals at 1.59 ppm, 2.50-2.40 ppm, 2.76 ppm and 
4.54 ppm confirm the incorporation of 3-[4-ferrocenylketobutamido]propylamine onto the 
conjugate. Spectrum of PD6 showed peaks at 0.98-0.96 ppm, 1.57 ppm and 2.49-2.38 ppm 
which indicate the presence of 3-diethylaminopropylamine. Signals at 1.57 ppm, 2.49-2.38 
ppm, 2.74 ppm and 4.51 ppm indicate the incorporation of the drugs; 3-[4-
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ferrocenylketobutamido]propylamine and potassium tetrachloroplatinate. The spectrum for 
PD7 displayed signals at 1.18 ppm, 1.77 ppm and 2.98-2.51 ppm which indicate the presence 
of 3-diethylaminopropylamine. On the other hand, signals at 1.77 ppm, 2.44-2.39 ppm, 2.98-
2.51 ppm and 4.54 ppm indicated presence of 3-[4-ferrocenylketobutamido]propylamine and 
cyclohexane-1,2-diamine dichloroplatinum(II). 
4.4 SEM analysis 
The polyamidoamine drug carriers and conjugates were further analysed by scanning electron 
microscopy to study surface morphology. Figure 4.7 and 4.8 displays micrographs of 
polyamidoamine drug carriers formed from selected amines, done at an accelerating voltage 
of 15 kV and viewed at various magnifications.  
The images for carriers PC1, PC2, PC3, PC4, PC5 and PC7 (fig 4.7 and fig 4.8) showed 
smooth surface morphology and folded morphology which can be attributed to the successful 
polyaddition of the amines to MBA (Aderibigbe et al., 2015). Carrier PC9 showed a 
combination of both smooth and cracked surface topology. SEM image for PC6, PC8 and 
PC10 displayed spherical and smooth surfaces of the carrier indicating successful reaction of 
MBA and the amines to form the polymer. The SEM images cement the suggestion from 
FTIR results that the polyamidoamine carriers were successfully formed from the reaction of 
MBA and the selected amines. 
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Figure 4.7: SEM images of polyamidoamine drug carriers PC1-5 
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Figure 4.8: SEM images of polyamidoamine drug carriers PC6-10 
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Figure 4.9: SEM images of polyamidoamine drug conjugates PD1-4 
 
The surface morphology of the drug conjugates PD1, PD2, PD3 and PD4 (fig 4.9) did not 
differ much from each other. They all showed smooth surfaces with swollen spherical 
topologies which can be attributed to the successful polyaddition of amines to the 
methylenebisacrylamide (Aderibigbe et al., 2015). PD1 and PD3 displayed some sections of 
rough surface topologies.  
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Figure 4.10: SEM images of polyamidoamine drug conjugates PD6-7 
SEM image for conjugate PD6 displayed flacks with rough edges morphology. Smooth 
surfaced blocks topology was observed for SEM image of conjugate PD7. 
4.5 EDX analysis 
The elemental composition of polyamidoamine drug conjugates was obtained using energy 
dispersive x-ray analysis. EDX analysis data indicated that platinum and ferrocene based 
drugs were successfully incorporated to the polyamidoamine carriers as shown on table 4.3 
below. The platinum content of the conjugates ranged from 1.59% in PD2 to 16.40% in PD6 
while iron composition varied between 0.22% and 0.38%. Carbon composition ranged from 
47.43% in PD7 to 25.52% in PD4. Nitrogen content was lowest at 3.15% in PD1 and highest 
at 18.70% for PD4. Oxygen composition varied from 13.32% to 39.0%. Chlorine content in 
the polyamidoamine drug conjugates ranged from 16.06% in PD6 to 23.38% in PD3. 
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 C % N % O % Cl % Pt % Fe % 
PD1 43.1 3.15 39.0 - 14.74 - 
PD2 29.16 18.35 23.68 27.22 1.59 - 
PD3 30.89 14.74 17.92 23.38 13.07 - 
PD4 25.52 18.70 21.42 20.84 13.52 - 
PD6 36.27 17.73 13.32 16.06 16.40 0.22 
PD7 47.43 17.78 14.03 17.77 2.60 0.38 
 
Table 4.3: Weight percent composition of drug conjugates from EDX data 
 
4.6 TEM analysis 
The polyamidoamine drug conjugates were also analysed by transmission electron 
microscopy to study the morphology. Figure 4.11 below displays micrographs of 
polyamidoamine drug conjugates. The sizes of particles can be estimated using the scale bar 
on the bottom left hand side of the images. 
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Figure 4.11: TEM images of polyamidoamine drug conjugates PD1-4 
 
TEM analysis was performed on selected conjugates PD1, PD2, PD3 and PD4 as shown on 
fig 4.11. The TEM micrographs displayed smooth spherical topologies which also correlate 
to spherically shaped morphology observed for surface morphology studies (SEM) of the 
conjugates. The sizes of the particles were obtained in the nanometre range. The size of the 
particles making up the conjugates observed by transmission electron microscopy studies 
were in line with results obtained in particle size analysis discussed in the section below. 
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4.7 Particle size analysis 
Compound Average Particle Size (nm)  PDI (±SD) Average Particle 
charge (±SD) 
PC10 376.4 ± 92.70                                                 0.390 ± 0.057 18.1 ± 6.35 
PD3 258.3 ± 46.52                                                   0.645 ± 0.158 30.2 ± 2.15 
PD5 280.3 ± 25.48                                                   0.533 ± 0.057 33.3 ± 4.54 
PD6 247.1 ± 36.21                                                   0.439 ± 0.125 29.0 ± 5.16 
 
Table 4.4: Average particle size, polydispersity index (PDI) and surface charge of selected 
polymer drug conjugates and carrier 
The polyamidoamine drug conjugate PD6 gave the smallest mean particle size (247.1 nm), 
followed by PD3 conjugate (258.3 nm), PD5 conjugate (280.3 nm) and PC10 carrier (376.4 
nm). The carrier has the highest particle size compared to drug conjugates. The size of the 
particles making up the conjugates obtained from particle size analysis are comparable to the 
particle sizes observed by transmission electron microscopy studies. The polydispersity index 
(PDI) was highest in the conjugate PD3 and the least value was obtained for carrier PC10 at 
0.390. The values for PDI are less than 1 indicating narrow molecular weight distribution 
which favours biomedical application of the polymers. Average particle charges ranged from 
18.1 in carrier PC10 to 33.3 for conjugate PD5.  
4.8 Drug release studies 
Figure 4.12 shows the drug release profiles for conjugates PD3, PD5 and PD6 performed at 
pH 1.2 and 7.4 at a temperature of 37C. All graphs showed a general trend of a sharp 
increase in the concentration of drug released that became steady after about 1500 minutes of 
the drug release experiments. Ferruti and co-workers reported similar drug release profiles of 
some of the PAA-platinates at pH 5.5 and 7.4 (Ferruti et al., 1999).  
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Figure 4.12: Percentage cumulative drug release profiles for (a) platinum drug release from 
PD3 at pH 1.2 (b) platinum drug release from PD3 at pH 7.4 (c) ferrocene drug release from 
PD5 at pH 1.2 (d) ferrocene drug release from PD5 at pH 7.4 (e) platinum drug release from 
PD6 at pH 1.2 (f) platinum drug release from PD6 at pH 7.4 (g) ferrocene drug release from 
PD6 at pH 1.2 (h) ferrocene drug release from PD6 at pH 7.4 
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Platinum drug release from conjugate PD3 at pH 1.2 was 51.4% after 5815 minutes. For the 
first 400 minutes, platinum drug release from conjugate PD3 was not linear but increased 
with time from 1495 minutes to 5815 minutes. On the other hand, platinum drug release for 
PD3 at pH 7.4 was faster in the first 400 minutes when 31.6% was released in the same 
period. 48.9% of drug was released in PD3 by 7300 minutes. The least amount of drug 
released from the conjugates was experienced in PD5 at pH 1.2 (fig 4.12c) where only 6% of 
the incorporated ferrocene drug was released in 5815 minutes of the experiment. 15.5% of 
drug was released in conjugate PD5 at pH 7.4 in the 7300 minutes carried out in the 
experiment. For conjugate PD6 at pH 1.2, 16.7% of the ferrocene drug was released in 7255 
minutes. 40.7% of the platinum drug was released from PD6 at pH 1.2 in 7255 minutes. The 
percentage of ferrocene drug released was 23.4% for PD6 at pH 7.4 in 7300 minutes while 
55.3% of platinum drug was released from conjugate PD6 at pH 7.4 in 7300 minutes of the 
experiment.  
   
   73 
 
Figure 4.13: Korsmeyer-Peppas graphs for (a) platinum drug release from PD3 at pH 1.2 (b) 
platinum drug release from PD3 at pH 7.4 (c) ferrocene drug release from PD5 at pH 1.2 (d) 
ferrocene drug release from PD5 at pH 7.4 (e) platinum drug release from PD6 at pH 1.2 (f) 
platinum drug release from PD6 at pH 7.4 (g) ferrocene drug release from PD6 at pH 1.2 (h) 
ferrocene drug release from PD6 at pH 7.4 
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The mechanism of drug release of the polyamidoamine drug conjugates performed at a 
temperature of 37C and at pH 1.2 and 7.4 was evaluated using Peppas equations 1 and 2 
(Ritger & Peppas, 1987).  
𝑀𝑡
𝑀𝑇
= 𝐾𝑡𝑛                                                                                  (1) 
𝑙𝑜𝑔
𝑀𝑡
𝑀𝑇
= 𝑛 log 𝑡 + log𝐾                                                           (2) 
where Mt stands for the amount of drug released at time t, MT is the total amount of 
polyamidoamine drug conjugate used, K is the kinetic constant and n is the diffusion or 
release exponent. Graphs of log (% Cumulative) against log (Time) of the experimental data 
were drawn and used to estimate diffusion exponent (n value). 
  Korsmeyer-Peppas parameters 
Polymer drug   
conjugate 
pH R2 n 
PD3 1.2 0.9705 0.1788 
7.4 0.9813 0.2012 
PD6 1.2 0.9494 0.313 
7.4 0.9787 0.2793 
 
Table 4.5: Drug release studies for platinum based drug in polyamidoamine drug conjugates 
PD3 and PD6 
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  Korsmeyer-Peppas parameters 
Polymer drug 
conjugate 
pH R2 n 
PD5 1.2 0.9778 0.1894 
7.4 0.9987 0.2787 
PD6 1.2 0.968 0.4018 
7.4 0.9933 0.3698 
 
Table 4.6: Drug release studies for Fc-PDA in polyamidoamine drug conjugates PD5 and 
PD6 at pH 1.2 and 7.4 
According to the conditions of Peppas equation, n < 0.5 indicates quasi-Fickian diffusion, n = 
0.5 corresponds to Fickian diffusion, 0.5 < n < 1 indicates anomalous or non-Fickian 
diffusion, n = 1 indicates case II (relaxation) transport while n > 1 corresponds to super case 
II transport (Costa & Lobo, 2001). The diffusion or release exponent (n values) for the drug 
release of the polyamidoamine conjugates at pH 1.2 and 7.4 was below 0.5 which indicate a 
quasi-Fickian diffusion mechanism.  
4.9 Cytotoxicity activity evaluation 
Samples of free drugs (K2PtCl4, Fc-PDA and DACH PtCl2), conjugates PD1-4,6,7 and carrier 
PC10 were tested for cytotoxicity against human breast cancer cell lines (MCF-7 and MDA-
MB-231) and normal cell lines (EA.hy926) as shown in table 7 below. Activities for the 
compounds are expressed as IC50, the concentration of compound required for 50% inhibition 
in vitro.  
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Compound 
                                         IC50 ± SEM (µM) 
MCF-7 MDA-MB-231 EA.hy926 
PD1  10.68 ± 1.123 12.19 ± 1.10 88.04 ± 1.097 
PD2  8.106 ± 1.224 9.353 ± 1.096 76.6 ± 1.096 
PD3 8.613 ± 1.179 11.48 ± 1.168 > 100 
PD4 12.45 ± 1.194 13.79 ± 1.175 > 100 
PD6  > 100 > 100 > 100  
PD7  1.455 ± 1.260 1.468 ± 1.209 > 100 
PC10  73.01 ± 1.42 67.94 ± 1.154 > 100 
K2PtCl4  > 100 > 100 > 100 
Fc-PDA  > 100 > 100 > 100 
DACH PtCl2 2.49 ± 1.15 > 100 15.68 ± 1.13 
Cisplatin  4.962 ± 1.267 4.124 ± 1.211 > 100 
 
Table 4.7: Table showing results for in vitro analysis 
 
The free drugs (K2PtCl4, Fc-PDA and DACH PtCl2) exhibited weak cytotoxicity against all 
cell lines when compared to free drug cisplatin except for DACH PtCl2 which showed good 
toxicity activity of 2.49 µM against MCF-7. The lack of cytotoxicity for Fc-PDA can be 
attributed to the presence of the ketone functional group next to the ferrocene ring since 4-
ferrocenylbutanoic acid which lack the ketone functional group has been reported to exhibit 
high electrochemical reduction potential (Neuse, 2001). All samples showed weak activity 
against normal cell lines (EA.hy926) indicating selectivity towards cancer cell lines used in 
this study. The carrier PC10 was not conjugated to any drug and it showed negligible 
cytotoxicity activity against all cell lines screened as expected. Previous studies have also 
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shown that polyamidoamines generally exhibit low toxicity against various cell lines 
(Richardson et al., 1999; Ranucci et al., 1991). From the data obtained, polyamidoamine drug 
conjugate PD7 produced the highest toxic activity against both cancer cell lines (MCF-7 and 
MDA-MB-231) with IC50 values <1.5 µM whereas PD6 showed the least activity of all 
conjugates evaluated. In general, the conjugates (PD1-4,6,7) showed more activity against 
MCF-7 cell line than the other cell lines tested.  
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CHAPTER 5  
___________________________________________________________________________ 
Conclusion and Recommendations 
5.1 Conclusion 
Analogues of platinum and ferrocene, polyamidoamine carriers and conjugates were 
successfully prepared and characterized by various techniques such as FTIR, 1H NMR, TEM, 
SEM and EDX. The polyamidoamine drug conjugates were formed from platinum and 
ferrocene based drugs by linking with amines. The conjugates particle size was obtained in 
the nanometre range as indicated by results from particle size analysis and transmission 
electron microscopy (TEM). The degree of conjugation of the drug onto the polymer varied 
from each conjugate. 
Drug release from the conjugates occurred faster in the initial stages but become fairly 
constant after about 24 hour of the drug release experiments at both pH 1.2 and 7.4 at a 
temperature of 37C. The highest percentage drug release was obtained for potassium 
tetrachloroplatinate drug release from conjugates PD3 and PD6. In PD3, 51.3% drug was 
released after 5815 minutes at pH 1.2 and 48.9% drug was released after 7300 minutes at pH 
7.4 while in PD6, 40.7% drug was released after 7255 minutes at pH 1.2 and 55.3% drug was 
released after 7300 minutes at a pH of 7.4. Drug release from all polyamidoamine drug 
conjugates tested followed quasi-Fickian diffusion mechanism according to Korsmeyer-
Peppas models for drug release. 
The parent compounds bound to a polyamidoamine carrier showed more cytotoxicity 
compared to the free drug hence polymer conjugation has proved to be useful in enhancement 
of anticancer properties of unconjugated drug molecules. The combination of two drugs Fc-
PDA and DACH PtCl2 in polyamidoamine drug conjugate PD7 enhanced the cytotoxicity of 
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drugs as observed by the good results of <1.5 µM which is significantly more pronounced 
than the singly conjugated polyamidoamine drug conjugates. However, the observations were 
not the same in the case of conjugate PD6 which is composed of Fc-PDA and K2PtCl4 drugs. 
5.2 Recommendations 
Objectives of the research project were achieved but improvements of the yield of carriers 
and conjugates is necessary. Although established procedures were followed, conditions 
should be improved to elevate the yield of product obtained from the synthetic reactions. 
Different linkers other than 1,3-propanediamine, 3-dimethylamino-1-propylamine, dopamine  
and 3-diethylaminopropylamine which were used in this study need to be assessed to find out 
if they have an impact on effectiveness of the polyamidoamine conjugates. In vivo studies 
should be carried out for the cytotoxic conjugates to explore the potential of the 
polyamidoamine conjugates in living organisms. Evaluation of drug release at pH 5.8 which 
represent the pH of the biological environment of tumour tissue is also necessary.  
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      Selected 1H NMR spectra 
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